课题基金 / 基金详情

LIPOSOMAL ANNAMYCIN IN TAXANE RESISTANT BREAST CANCER

LIPOSOMAL ANNAMYCIN IN TAXANE RESISTANT BREAST CANCER
脂质体安那霉素治疗紫杉烷抗性乳腺癌
批准号：
6264179
负责人：
ADAM M BRUFSKY
金额：
$0.3万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264179
关键词：
anthracyclines breast neoplasms clinical research drug resistance human subject human therapy evaluation intravenous administration neoplasm /cancer chemotherapy paclitaxel

项目摘要

项目成果

ADAM M BRUFSKY的其他基金

相似基金

相关文献

中文摘要
翻译
研究的第一阶段包括传统的剂量递增研究，以确定该患者群体中安纳霉素的最大耐受剂量。研究的第二阶段调查在最大耐受剂量下的反应。在最大耐受剂量确定后，共有14名患者将在该剂量水平下接受治疗。Annamycin将在门诊每21天静脉注射至少两个疗程的治疗，并将继续研究，直到毒性严重或两个周期超过持续可测量的反应。大约2名患者将参与这项研究。
英文摘要
The first phase of the study consists of a traditional dose escalation study to determine the maximum tolerated dose of Annamycin in this patient population. The second phase of the study investiages response at the maximum tolerated dose. After the maximum tolerated dose is determined, a total of 14 patients will be treated at that dose level. Annamycin will be administered intravenously every 21 days in the outpatient setting for a minimumof two courses of therapy and will remain on study until toxicity is severe or two cycles past a sustained mesurable response. Approximately 2 patients will participate in the study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
海外基金